



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/954,695	09/11/2001	Melissa M. Cunningham	GP116-02.UT	8611
21365	7590	02/22/2005	EXAMINER	
GEN PROBE INCORPORATED 10210 GENETIC CENTER DRIVE SAN DIEGO, CA 92121			GOLDBERG, JEANINE ANNE	
			ART UNIT	PAPER NUMBER
			1634	

DATE MAILED: 02/22/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

09/954,695

Applicant(s)

CUNNINGHAM ET AL.

Examiner

Jeanine A Goldberg

Art Unit

1634

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 06 December 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) See Continuation Sheet is/are pending in the application.
- 4a) Of the above claim(s) 21 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) See Continuation Sheet is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

Continuation of Disposition of Claims: Claims pending in the application are 1,7,8,10-16,18,19,21,23,33-37,40,41,43,45,50,51,53,54,61,62,73,74,83,85,88,97,98,106-108,110-113,130-136,138,140,142,144,146,148,150,151,153 and 155.

Continuation of Disposition of Claims: Claims rejected are 1,7,8,10-16,18,19,23,33-37,40,41,43,45,50,51,53,54,61,62,73,74,83,85,88,97,98,106-108,110-113,130-136,138,140,142,144,146,148,150,151,153 and 155.

### **DETAILED ACTION**

1. This action is in response to the papers filed December 6, 2204. Currently, claims 1, 7-8, 10-16, 18-19, 21, 23, 33-37, 40-41, 43, 45, 50-51, 53-54, 61-62, 73-74, 83, 85, 88, 97-98, 106-108, 110-113, 130-135, 136, 138, 140, 142, 144, 146, 148, 150-151, 153, 155 are pending.
2. Claim 21 is withdrawn as drawn to non-elected subject matter. The response argues that the examiner does not permit the applicant to claim a preferred probe mix. As provided in the restriction requirement the applicant was requested to select a single combination. Applicant did not select such probe for the combination. However, upon allowance of Claim 19, the examiner will rejoin the probe of Claim 21.
3. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on December 8, 2004 has been entered.

### ***Priority***

4. This application claims priority to U.S. Provisional Application No. 60/232,028, filed September 12, 2000.

***Drawings***

5. The drawings are acceptable.

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

6. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

7. Claims 1, 10, 15-16, 18-19, 23, 40-41, 43, 45, 50-51, 53-54, 61-62, 73-74, 83, 85, 88, 97-98, 106-108, 110-113, 130-135, 136, 138, 140, 142, 144, 146, 148, 150-151, 153, 155 are rejected under 35 U.S.C. 103(a) as being unpatentable over Zhu et al. (J. of Infectious Disease, Vol. 177, pages 1443-1446, 1998) in view of Fenger et al. (US Pat. 6,110,665, August 2000) and Wick (US Pat. 6,063,604, May 16, 2000) and

Williams (US Pat. 6,146,855, November 2000) in view of Hogan (US Pat. 5,595,874, January 1997).

The broad product claims have also been rejected in this 103 rejection in the event that the claims were amended to narrow the claims to recite consisting of SEQ ID NO: 1, 21, 22, for example.

Zhu et al. (herein referred to as Zhu) teaches a method of detecting *Cryptosporidium* using genus specific primers from the 18S rRNA. The target DNA for PCR was the small subunit rRNA gene (srDNA).

Zhu does not specifically teach using SEQ ID NO: 1 as a target sequence for the probes and primers.

However, Fenger et al. (herein referred to as Fenger) provides an alignment for the relatedness of a 450 nt sequence from SRSU of several genus of organisms including *C. parvum*. SEQ ID NO: 1, 21, 22 are embedded within the alignment. SEQ ID NO: 1 and 21 are located within SEQ ID NO: 27 of Figure 1A. SEQ ID NO: 22 is located within SEQ ID NO: 37 of Figure 1B. SEQ ID NO: 48 is located within SEQ ID NO: 47 of Figure 1B. SEQ ID NO: 1 is found in a region which contains 5 mismatches as compared to regions flanking which contain fewer regions of variability. Therefore, selecting a region with variability will provide more specific detection.

Additionally, Wick provides the entire 18S rRNA gene of *Cryptosporidium parvum*. SEQ ID NO: 1, 21, 48 are located within the sequence.

Finally, Williams provides an alignment of three *Cryptosporidium* sequences, namely *C. parvum*, *C. muris* and *C. baileyi* over the 18S region. SEQ ID NO: 1 is

Art Unit: 1634

embedded in a region which is entirely conserved among the *Cryptosporidium* sequences. Williams' alignment comprises SEQ ID NO: 45, 46, 21, 1, 22, 48 (limitations of claim 41, 43, 45)

Moreover, Hogan teaches a method which compares one or more sequence rRNA variable regions from a target organism to one or more rRNA variable region sequences from closely related species that can be utilized to distinguish between such organisms. Hogan teaches the use of specific primers col. 6-7, lines 50-67, lines 1-12, and furthermore provides specific guidance for the selection of primers,

"Once the variable regions are identified, the sequences are aligned to reveal areas of maximum homology or 'match'. At this point, the sequences are examined to identify potential probe regions. Two important objectives in designing a probe are to maximize homology to the target sequence(s) (greater than 90% homology is recommended) and to minimize homology to non-target sequence(s) (less than 90% homology to non-targets is recommended). We have identified the following useful guidelines for designing probes with the desired characteristics.

First, probes should be positioned so as to minimize the stability of the probe:nontarget nucleic acid hybrid. This may be accomplished by minimizing the length of perfect complementarity to non-target organisms, avoiding G and C rich regions of homology to non-target sequences, and by positioning the probe to span as many destabilizing mismatches as possible (for example, dG:rU base pairs are less destabilizing than some others). Second, the stability of the probe:target nucleic acid hybrid should be maximized. This may be accomplished by avoiding long A and T rich sequences, by terminating the hybrids with G:C base pairs and by designing the probe with an appropriate  $T_m$ . The beginning and end points of the probe should be chosen so that the length and %G and %C result in a  $T_m$  about 2-10°C higher than the temperature at which the final assay will be performed. The importance and effect of various assay conditions will be explained further herein. Third, regions of the rRNA which are known to form strong structures inhibitory to hybridization are less preferred. Finally, probes with extensive self complementarity should be avoided."

Hogan teaches that "while oligonucleotide probes of different lengths and base composition may be used, oligonucleotide probes preferred in this invention are between about 15 and about 50 bases in length" (col. 10, lines 13-15)(limitations of Claim 1). Oligonucleotides complementary to sequences adjacent to the probe regions were synthesized and used in the hybridization mix according to Hogan et al., U.S. Pat. No. 5,030,557; filed Nov. 24, 1987, entitled "Means and Method for Enhancing Nucleic Acid Hybridization (the "helper " patent application). Hogan teaches that oligonucleotide probes may be labeled by any of several well known methods such as radioisotopes, non-radioactive reporting groups, non-isotopic materials such as fluorescent molecules (col. 10, lines 45-60). Hogan teaches that probes may be labeled using a variety of labels, as described within, and may be incorporated into diagnostic kits (limitations of Claims 74, 88, 135-155).

Therefore, it would have been prima facie obvious to one of ordinary skill at the time the invention was made to have modified the genus specific PCR primers taught by Zhu using the alignment provided by Fenger and Williams, the full length sequence of Wick and the specific guidance provided by Hogan to obtain the invention as a whole. The primer of Zhu is located upstream of SEQ ID NO 21, 1, 22, 48, for example. Given the teachings in the art directed to modifying probes and primers to obtain functional equivalents, the ordinary artisan would have been motivated to have selected any other probe or primer which would function to detect the genus *Cryptosporidium*. Since the claimed primers simply represent functional equivalents of the probes and primers of Zhu, a biochemist of ordinary skill would attempt to obtain alternate compounds with



Art Unit: 1634

improved properties, the claimed primers and probes are *prima facie* obvious over the cited reference in the absence of secondary considerations. The specific probes, absent any unexpected results with the instantly claimed SEQ ID NO:s, the instantly claimed genus-specific probes are considered to be functionally equivalent to those of Zhu because they are located within the same region, namely the 18S rRNA as the instantly claimed oligonucleotides and those of Zhu and further because Zhu teaches the usefulness of the 18S region for detecting *Cryptosporidium*.

With respect to Claim 15, the conditions are provided, however the claims are drawn to a product which would hybridize necessarily under these conditions because there is 100% complementary.

The art also teaches that one of skill in the art can modify the disclosed genus specific primer to enhance the properties based on factors such as probe length, melting temperature, and sequence content. Additionally, at the time the invention was made, the sequence of the *Cryptosporidium* nucleic acids of distinct types were known and it would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made and within the skill of the art to obtain the instantly claimed oligonucleotides following the teachings of Hogan as to the identification of sequences that are genus specific and thus useful for the identification of *Cryptosporidium* by hybridization. Further, the teachings of Zhu, Fenger and Hogan indicate that the state of the art at the time the invention was made would have led one of ordinary skill in the art to the claimed genus-specific probes because Zhu, Fenger and Hogan teaches the

usefulness of the 18S region of the *Cryptosporidium* for genus-specific probes, genus-specific primers and further teaches methods in which the probes may be modified.

### **Response to Arguments**

The response traverses the rejection. The response asserts that "whether the claimed compounds perform the same function is not the standard established by the Court in *In re Deuel*." This argument has been thoroughly considered and not found persuasive. *Deuel* teaches structural relationships may provide the requisite motivation or suggestion to modify known compounds to obtain new compounds. *Deuel* teaches that a prior art compound may suggest its homologs because homologs often have similar properties and therefore chemists of ordinary skill would ordinarily contemplate making them to try to obtain compounds with improved properties. The primers and probes are homologues of one another and of the full length. The prior art teaches genus specific probes and primers to *Cryptosporidium*. The prior art teaches the full length region. Designing primers and probes which are equivalents to those taught in the art is routine experimentation. The prior art teaches the parameters and objectives involved in the selection of oligonucleotides that function as probes and primers, see Hogan et al. Moreover there are many internet web sites that provide free downloadable software to aid in the selection of primers drawn from genetic data recorded in a spreadsheet. The prior art is replete with guidance and information necessary to permit the ordinary artisan in the field of nucleic acid detection to design primers and probes. As discussed above, the ordinary artisan would be motivated to have designed and tested new primers or probes to obtain additional oligonucleotides

that function to detect *Cryptosporidium* and identify oligonucleotides with improved properties.

Applicants are encouraged to provide any evidence or showing of non-obviousness of the claimed probes and primers, presented in declaration form.

The response asserts that the combination teaches away from the claimed invention. The response asserts that the teachings of Fenger would suggest designing probes and primers to Figure 1E that has significantly greater variability than the region disclosed in Figure 1A. This argument has been thoroughly considered and not found persuasive because the existence of an additional region with high variability, absent unexpected results, would not render non-obvious an alternative region of variability between *genuses*. As discussed above, regions of variability would be expected to function in discriminating between different genus and regions of similarity between species within *Cyprosporidium* would function to identify the larger genus.

Thus, for the reasons set forth above, and previously, the rejection is maintained.

8. Claims 7-8, 11-14, 33-37 are rejected under 35 U.S.C. 103(a) as being unpatentable over Zhu et al. (J. of Infectious Disease, Vol. 177, pages 1443-1446, 1998) in view of Fenger et al. (US Pat. 6,110,665, August 2000) and Wick (US Pat. 6,063,604, May 16, 2000) in view of Hogan (US Pat. 5,595,874, January 1997) as applied to Claims 1-6, 10, 13-15, 16-19, 23, 30-31, 38-41, 43, 45, 50-54, 61-62, 71-74, 83, 85, 92-155 above, and further in view of Becker et al. (US Pat. 6,361,945, March 26, 2002).

Neither Zhu, Fenger, Wick or Hogan specifically teach a method using interacting labels including luminescent label and quencher labels.

However, Becker teaches a method of using "molecule torches" for detecting the presence of a target nucleic acid sequence. Becker teaches the molecular torches contain a target binding domain, a target closing domain and a joining region (col. 2, lines 15-25)(limitations of Claims 7-8). The target binding domain is biased towards the target sequence. A luminescent/quencher pair is preferably used (col. 9, lines 45-60)(limitations of Claims 11-12). Moreover, Becker teaches using 2'-methoxy substituted ribonucleotides (col. 10, lines 55-65)(limitations of Claim 13). Becker teaches "one of the advantages of using the present invention in conjunction with a transcription-associated amplification is that the molecular torch can be added prior to amplification, and detection can be carried out without adding additional reagents (col. 12, lines 10-20). Becker teaches using pseudo peptide backbones (col. 8)(limitations of Claim 14).

Therefore, it would have been prima facie obvious to one of ordinary skill at the time the invention was made to have modified the PCR detection assay of Hogan to encompass the use of molecular torches of Becker. Becker teaches that there are numerous means for detecting probes designed to preferentially hybridize to the target sequence. Therefore, the method of Becker is an equivalent method as the method of Hogan which enables the detection of nucleic acid binding.

#### **Response to Arguments**

The response traverses the rejection. The response asserts that the Becker reference does not cure the deficiencies. This argument has been reviewed but is not convincing because the rejection of the previous rejection is maintained for the reasons presented above. Thus for the reasons above and those already of record, the rejection is maintained.

***Claim Rejections - 35 USC § 112-Description***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

9. Claims 1, 7-8, 10-16, 18-19, 23, 33-37, 40-41, 43, 45, 50-51, 53-54, 61-62, 73-74, 83, 85, 88, 97-98, 106-108, 110-113, 130-135, 136, 138, 140, 142, 144, 146, 148, 150-151, 153, 155 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The claims are broadly drawn to probes, primer and methods for detecting *Cryptosporidium*.

The specification has provided specific sequences of SEQ ID NO: 1, 21, 48 for use in detecting *Cryptosporidium* but not nucleic acids derived from non-*Cryptosporidium* organisms.

*Vas-Cath Inc. V. Mahurkar*, 19 USPQ2b 1111, clearly states that “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the ‘written description’ inquiry, whatever is now claimed”. Applicant is reminded that *Vas-Cath* makes clear that the written description provision of 35 USC 112 is severable from its enablement provision. In *The Regents of the University of California v. Eli Lilly* (43 USPQ2b 1398-1412), the court held that a generic statement which defines a genus of nucleic acids by only their functional activity does not provide an adequate written description of the genus. The court indicated that while Applicants are not required to disclose every species encompassed by a genus, the description of a genus is achieved by the recitation of a representative number of DNA molecules, usually defined by a nucleotide sequence, falling within the scope of the claimed genus. At section B(1), the court states that “An adequate written description of a DNA...’ required a precise definition, such as by structure, formula, chemical name, or physical properties’, not a mere wish or plan for obtaining the claimed chemical invention”. In analyzing whether the written description requirement is met for a genus claim, it is first determined whether a representative number of species have been described by their complete structure. In the instant case, there is no actual reduction to practice of the claimed invention, clear depiction of the claimed invention in the drawings or complete detailed description of the structure. A review of the language of the claim indicates that the claim is drawn to a genus, i.e., any nucleic acid that minimally hybridizes to a nucleic acid derived from a *Cryptosporidium* organism in a test sample which fully hybridizes to

the target sequence of SEQ ID NO: 1. The partial structure provided within the claim broadly encompasses variant 18S rRNA, homologous 18S rRNA and nucleic acid sequences yet to be discovered. There is substantial variability among the species of DNAs encompassed within the scope of the claims because a nucleic acid which hybridizes to a nucleic acid derived from a *Cryptosporidium* organism in a test sample which fully hybridizes to the target sequence of SEQ ID NO: 1 is only a fragment. It is unclear whether fully hybridizes means that there is 100% complementary between the probe and that target or whether the probe hybridizes over the full length, but encompasses mismatches within the binding. The response filed December 6, 2004 asserts that "fully hybridizes" is mean that hybridization of the target binding region to the target nucleic acid is limited to the region of the target nucleic acid defined by the recited target sequence (page 24 of response filed December 6, 2004). This definition does not appear to be found in the specification. Based upon the dependent claims which further limit "fully hybridizes" with perfectly complementary, fully hybridizes something less than perfectly complementary, however, fully hybridizes does not appear to be defined. A description of a genus of nucleic acids may be achieve by means of a recitation of a representative number of nucleic acids, defined by nucleotide sequence, falling within the scope of the gnus or of a recitation of structural features common to the members of the genus, which features constitute a substantial portion of the genus. Therefore, weighing all factors, 1) partial structure of the DNAs that hybridizes to a nucleic acid derived from a *Cryptosporidium* organism in a test sample which which fully hybridizes to the target sequence of SEQ ID NO: 1, 2) the breadth of

Art Unit: 1634

the claim, 3) the lack of correlation between the structure and function; in view of the level of knowledge and skill in the art, one skilled in the art would not recognize from the disclosure that the applicant was in possession of the genus of nucleic acids hybridizes to a nucleic acid derived from a *Cryptosporidium* organism in a test sample which is at least 80% complementary to the target sequence of SEQ ID NO: 1, for example.

**Response to Arguments**

The response traverses the rejection. The response asserts that the claim has been amended to require "fully hybridizes." This argument has been considered but is not convincing because the specification does not appear to clearly indicate what is encompassed by fully hybridizes. Thus for the reasons above and those already of record, the rejection is maintained.

***Claim Rejections - 35 USC § 112***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

10. Claims 1, 7-8, 10-16, 18-19, 21, 23, 33-37, 40-41, 43, 45, 50-51, 53-54, 61-62, 73-74, 83, 85, 88, 97-98, 106-108, 110-113, 130-135, 136, 138, 140, 142, 144, 146, 148, 150-151, 153, 155 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

A) Claims 1, 7-8, 10-16, 18-19, 21, 23, 33-37, 40-41, 43, 45, 50-51, 53-54, 61-62, 73-74, 83, 85, 88, 97-98, 106-108, 110-113, 130-135, 136, 138, 140, 142, 144, 146,



Art Unit: 1634

148, 150-151, 153, 155 has been amended to require a target binding region, a target sequence, a target nucleic acid and a test sample. It is entirely confusing what is required to hybridize and bind to which target sequences or binding regions. It is unclear whether fully hybridizes means that there is 100% complementary between the probe and that target or whether the probe hybridizes over the full length, but encompasses mismatches within the binding. The response filed December 6, 2004 asserts that "fully hybridizes" is mean that hybridization of the target binding region to the target nucleic acid is limited to the region of the target nucleic acid defined by the recited target sequence (page 24 of response filed December 6, 2004). This definition does not appear to be found in the specification. Based upon the dependent claims which further limit "fully hybridizes" with perfectly complementary, fully hybridizes something less than perfectly complementary, however, fully hybridizes does not appear to be defined. Thus, the metes and bounds of the claims are unclear.

### ***Conclusion***

**11. No claims allowable.**

12. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

A) Rochelle et al. (Applied and Environmental Microbiology, Vol. 63, No. 1, pages 106-114, January 1997) teaches a method of using primers to the 18S to distinguish between *Crptosporidium parvum* and *Giardia lamblia* in water.

13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner Jeanine Goldberg whose telephone number is


Art Unit: 1634

(571) 272-0743. The examiner can normally be reached Monday-Friday from 7:00 a.m. to 4:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones, can be reached on (571) 272- 0745.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

The Central Fax Number for official correspondence is (571) 273-8300.

  
**Jeanine Goldberg**  
**Primary Examiner**  
February 18, 2005